retatrutide approval status 2025 retatrutide fda approval Commercial Availability Timeline: Key Milestones and Costs The FDA has issued warning

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) become more widely prescribed for weight loss, questions about nutrient depletion and vitamin requirements have increased

One in five people taking retatrutide 12mg developed abnormal touch sensations tingling, numbness, uncomfortable feelings when touched

97 Finally, these medications have shown to improve cardiorespiratory fitness

At Set Point Medical Weight Loss Clinic, we offer a personalized, medically supervised approach to weight management, incorporating semaglutide GLP-1 as a cornerstone for sustainable weight loss

At the weight-management dose of 2.4 mg, the largest pooled analysis of four placebo-controlled trials in 3,087 adults without diabetes found an average weight loss of 12.1% (about 12.3 kg) at 68 weeks compared to placebo, and 33% of participants lost at least 20% of their starting weight

The American Diabetes Association Standards of Care acknowledge the theoretical pancreatitis concern with incretin-based therapies but do not recommend avoiding these medications based on current evidence, emphasizing individualized risk-benefit assessment